Kevzara market forecast sees growth through 2030

The Kevzara market is projected to expand through 2030 as rheumatoid arthritis and other autoimmune diseases rise, biologic use widens, and healthcare spending increases. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Kevzara sits in a growing biologics market tied to chronic autoimmune disease care. - Rising rheumatoid arthritis cases and broader use of targeted therapies are supporting demand for the drug. - Higher healthcare spending can lift use of specialty medicines that require ongoing treatment.

What happened: - The Business Research Company published its Kevzara Market Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Kevzara market is being shaped by changing healthcare needs and treatment advances. - The report highlights North America as the largest market in 2025. - The report identifies Asia-Pacific as the fastest-growing region over the forecast period. - Download a free sample of the Kevzara market report.

The details: - Kevzara is a biologic prescription medicine classified as a monoclonal antibody for adults with moderate to severe rheumatoid arthritis. - The drug blocks interleukin-6, or IL-6, which plays a central role in inflammation. - By inhibiting IL-6 receptors, Kevzara reduces inflammation and eases rheumatoid arthritis symptoms. - Healthcare providers may also prescribe Kevzara for other inflammatory diseases, depending on patient needs. - Historic market growth was driven by high rheumatoid arthritis prevalence, limitations of traditional DMARDs, clinical success for biologics, better access to specialized rheumatology care and improved diagnosis rates. - The forecast period is expected to benefit from a rising autoimmune disease burden, Kevzara’s expansion into additional inflammatory conditions, broader acceptance of biologics, improved access to specialty care and innovation targeting cytokine pathways. - Key trends include greater adoption of IL-6 inhibitors, increased use of biologics for rheumatoid arthritis, expansion of targeted anti-inflammatory drugs, preference for injectable biologics and demand for long-term disease control. - The company says the report also covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The updated 2026 report package includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspots infographics, and key technology and future trend analysis.

Between the lines: - The report positions Kevzara as part of a broader shift toward targeted immune therapies rather than older treatment approaches. - The growth case depends less on a single drug factor and more on the combination of disease prevalence, specialty-care access and higher spending on biologics. - The regional split suggests mature markets are driving current demand, while emerging healthcare systems may create the next wave of growth. - Arthritis Australia projected in February 2024 that the number of Australians living with arthritis will rise from 4.11 million in 2025 to 5.39 million by 2040, with rheumatoid arthritis cases reaching 748,721. - The UK Office for National Statistics reported in May 2024 that healthcare expenditure rose 5.6% nominally from 2022 to 2023, compared with 0.9% growth in 2022.

What's next: - Market growth will likely track autoimmune disease prevalence, specialty-care access and broader biologic adoption. - Asia-Pacific is expected to be the key growth region as healthcare access expands and advanced therapies gain ground. - The report’s forecast horizon runs through 2035, giving investors and drugmakers a longer view of demand trends.

The bottom line: - Kevzara’s market story is being driven by the same forces reshaping autoimmune care overall: more patients, more biologic use and more spending on specialty treatment.